ReviewCNS drugs2022
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment.
Review in CNS drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06496087 (Evaluation of DEPREXIL Treatment in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment), which is not on this map. Cited by 94 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of DEPREXIL Treatment in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment
Who cites it
94 citing papers in PubMed, 4 syntheses or guidelines pooled it, 204 citations in OpenAlex.
- Brain microstructural alterations in COVID-19: a systematic review of diffusion weighted imaging studies.Brain imaging and behavior · 2026Pooled it
- Clinical efficacy of fecal microbiota transplantation in alleviating depressive symptoms: a meta-analysis of randomized trials.Frontiers in psychiatry · 2025Pooled it
- Mental health of Canadian youth: A systematic review and meta-analysis of studies examining changes in depression, anxiety, and suicide-related outcomes during the COVID-19 pandemic.Canadian journal of public health = Revue canadienne de sante publique · 2024Pooled it
- Effects of exercise therapy on anxiety and depression in patients with COVID-19: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- A digital intervention for cognitive deficits following COVID-19: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis.Advances in therapy · 2024Trial
- Neurocognitive and psychological symptoms in post COVID-19 patients (PASC24): prospective cohort study protocol.BMJ open · 2026Observational
- Depression and anxiety symptom severity correlates with subjective fatigue characteristics in individuals with anxiety and mood disorders.BMC psychiatry · 2026Article
- Circulating mitochondrial and cellular damage markers in long COVID: Links to cognitive function, psychological distress, and inflammation.Molecular psychiatry · 2026Article
- Psychopathologies in post-COVID outpatients differ from a psychosomatic control sample in a cross-sectional study.Discover mental health · 2026Article
- The role of genetic liability for psychiatric disorders and personality traits in post covid syndrome: data from three Nordic population cohorts.EClinicalMedicine · 2026Article
- Review
- Healthcare Consumption and Work Absenteeism of Individuals With and Without Persistent Complaints After COVID-19: The Role of Cognitive-Behavioural Factors, Neuropsychological Functioning and Depressive Symptoms.International journal of behavioral medicine · 2026Article
- CRHR1 Gene Copy Number Variations, Chronic Viral Infections, and Age as Correlates of Cognitive Impairment in Adults After SARS-CoV-2 Infection.Current issues in molecular biology · 2026Article
- Factorial structure of the patient health questionnaire-9 in long-term survivors of severe COVID-19.Frontiers in psychology · 2026Article
- The impact of the COVID-19 pandemic on the global burden of mental disorders: a counterfactual modeling study from 1990 to 2021.Translational psychiatry · 2025Article
- Observational
- Evidence for a severe cognitive subgroup in a comprehensive neuropsychological Post-COVID-19 syndrome classification.Scientific reports · 2025Article
- The Role of Probiotics and Their Postbiotic Metabolites in Post-COVID-19 Syndrome.Molecules (Basel, Switzerland) · 2025Review
- Post-pandemic mental health: Understanding the global psychological burden and charting future research priorities.World journal of psychiatry · 2025Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors such as depression, anxiety, and cognitive impairments are now recognized as primary symptoms of the "post-acute COVID-19 syndrome." Depressive psychopathology was reported in around 35% of patients at short, medium, and long-term follow-up after the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. Post-COVID-19 depressive symptoms are known to increase fatigue and affect neurocognitive functioning, sleep, quality of life, and global functioning in COVID-19 survivors. The psychopathological mechanisms underlying post-COVID-19 depressive symptoms are mainly related to the inflammation triggered by the peripheral immune-inflammatory response to the viral infection and to the persistent psychological burden during and after infection. The large number of SARS-CoV-2-infected patients and the high prevalence of post-COVID-19 depressive symptoms may significantly increase the pool of people suffering from depressive disorders. Therefore, it is essential to screen, diagnose, treat, and monitor COVID-19 survivors' psychopathology to counteract the depression disease burden and related years of life lived with disability. This paper reviews the current literature in order to synthesize the available evidence regarding epidemiology, clinical features, neurobiological underpinning, and pharmacological treatment of post-COVID-19 depressive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.